Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2000-02-04
2010-06-08
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S186100, C424S209100, C435S069100
Reexamination Certificate
active
07731972
ABSTRACT:
The present invention relates to an influenza antigen, comprising a fusion product of at least (1) the extracellular part of a conserved influenza membrane protein (e.g., M2) or a functional equivalent thereof and (2) a presenting carrier. The presenting carrier may be a (poly)peptide or a non-peptidic structure such as glycans, peptide mimetics, and synthetic polymers. The invention further relates to methods of making and using the antigen, and to influenza vaccines comprising the antigen and optionally one or more excipients.
REFERENCES:
patent: 3919044 (1975-11-01), Melnick et al.
patent: 5691189 (1997-11-01), Kurtz et al.
patent: 5843446 (1998-12-01), Ladd et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5919480 (1999-07-01), Kedar et al.
patent: 49273 90 (1990-08-01), None
patent: A-49273/90 (1990-08-01), None
patent: WO 92/22575 (1992-12-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 01/49886 (2001-07-01), None
patent: WO 01/49886 (2001-07-01), None
patent: WO 01/59886 (2001-07-01), None
Dorland's Illustrated dictionary. 1994, 28th edition. Philadelphia; WB Sauders Company, p. 1254.
Fields et al. Virology, 3rd edition 1996. Philadelphia; Lippencott, Williams, and Wilkins, pp. 1400 and 1417.
Cruse et al. (Illustrated Dictionary of Immunlogy. 1995. CRC Press, Boca Raton, pp. 46 and 229.
Estabrook et al. J Invest Surg 1989; 2 (3): 211-22, abstract only.
Gray et al. Protein Science. 1998; 7 (11): 2359-73, abstract only.
Zebedee et al. Journal of Virology. 1988; 62 (8): 2762-2772.
Slepushkin et al. Vaccine. 1995; 13 (15): 1399-1402.
Heinen et al. Journal of General Virology. 2002; 83: 1851-1859.
Thimme et al. Virology. 1995; 211: 296-301.
Jegerlehner et al. Journal of Immunology. 2004; 172: 5598-5605.
Chen et al. Vaccine. 2001; 19:1446-1455.
Zharikova et al. Journal of Virology. Jun. 2005; 79 (11): 6644-6654.
Sunstrom et al. Ion Channels Formed by NB, an Influenza V Virus Protein, J. Membrane Biol. 1996, 150:127-132.
van de Guchte et al., Applied and Environmental Microbiology, 1989, 55(1):224-228.
Pouwels et al, “The Potential OfLactobacillusAs A Carrier For Oral Immunization: Development And Preliminary Characterization Of Vector Systems For Targeted Delivery Of Antigens”,The Journal of Biotechnology44:183-192 (1996).
Sansom et al, “Influenza Virus M2Protein: A Molecular Modelling Study Of The Ion Channel”,Protein Engineering6:65-74 (1993).
Tosteson et al, “Reconstruction Of The Influenza Virus M2Ion Channel In Lipid Bilayers”,The Journal of Membrane Biology142:117-126 (1994).
Heinen, et al., “Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus”, J. of Gen. Virol. 83:1851-1859 (2002).
Lamb et al., “Influenza Virus M2Protein Is an Integral Membrane Protein Expressed on the Infected-Cell Surface”, Cell., 40:627-633 (1985).
Fan et al.,Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys, Vaccine 22:2993-3003 (2004).
Monto, et al.,Clinical Signs and Symptoms Predicting Influenza Infection, Archive of Internal Medicine, 160:3243-3247 (2000).
Opposition Letter dated Sep. 4, 2006 to European Patent No. EP 0 996 717 B1.
Notice of Opposition to European Patent No. EP 0 996 717 B1 dated Sep. 5, 2006.
Opposition Letter dated Sep. 5, 2006 to European Patent No. EP 0 996 717 B1.
Opposition Letter dated Sep. 7, 2006 to European Patent No. EP 0 996 717 B1.
Slepushkin et al., Vaccine, vol. 13, No. 15, pp. 1399-1402, 1995 “Protection of Mice Against Influenza a Virus Challenge by Vaccination with Baculovirus-Expressed M2 Protein”.
Pouwels et al.,Journal of Biotechnology44 (1996) 183-192 “The Potential ofLactobacillusas a Carrier for Oral Immunization: Development and Preliminary Characterization of Vector Systems for Targeted Delivery of Antigens”.
(English version) Insertie Van Nucleoproterne T-Cel Epitoop Van Het Influenza A Virus in Het M2-Hepatitis B Core Fusie-Eiwit, by Bart Bamps, Promotor: Professor Willy Min Jou, Begeleider: Sabine Neirynck, Laboratorium voor Moleculaire Biologie VIB, Universiteit GENT, Academiejaar 1996-1997, Academic Degree obtained Jul. 2, 1997.
(English version) Een Expressieplasmide Leidend Tot De Presentatie Van Influenza M2 Eiwitepitopen Op Het E. Coli Celoppervlak, by Sabine Neirynck, Promotor: Professor W. Fiers, Laboratorium voor Moleculaire Biologie VIB, Rijksuniversiteit GENT, Academiejaar 1987-1988, Academic Degree obtained Sep. 30, 1988.
Lamb, R.A. et al., “Influenza Virus M2Protein is an Integral Membrane Protein Expressed on the Infected-Cell Surface,”Cell 40:627-633 (1985).
Charbit, A., et al., “Probing the Topology of a Bacterial Membrane Protein by Genetic Insertion of a Foreign Epitope; Expression at the Cell Surface,”EMBO J.5:3029-3037 (1986).
Charbit, A., et al., Presentation of Two Epitopes of the preS2 Region of Hepatitis B Virus on Live Recombinant Bacteria,J. Immunol.,139:1658-1664 (1987).
Francis, M.J., et al., “Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein,” In: Antibodies, Antigens, and Molecular Mimicry, Methods in Enzymology vol. 178, J.J. Lagone, editor, pp. 659-676, Academic Press, Inc., New York (1989).
Borisova, G.P., et al., “Recombinant Core Particles of Hepatitis B Virus Exposing Foreign Antigenic Determinants on Their Surface,”FEBS Letters259: 121-124 (1989).
Clarke, B.E., et al., “Presentation and Immunogenicity of Viral Epitopes on the Surface of a Hybrid Hepatitis B Virus Core Particles Produced in Bacteria,”J. General Virology71: 1109-1117 (1990).
Francis, M.J., et al., “Immunological Properties of Hepatitis B Core Antigen Fusion Proteins,”Proc. Natl. Acad. Sci. 87:2545-2549 (1990).
Clarke, B.E., et al., “Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core Protein,”Nature 330:381-384 (1987).
Brown, A.L., et al, “Foreign Epitopes in Immunodominant Regions of Hepatitis B Core Particles are Highly Immunogenic and Conformationally Restricted,”Vaccine9:595-601 (1991).
von Brunn, A., et al., “Principal Neutralizing Domain of HIV-1 is Highly Immunogenic when Expressed on the Surface of Hepatitis B Core Particles,”Vaccine11:817-824 (1993).
Pumpens, P., et al., “Hepatitis B Virus Core Particles as Epitope Carriers,” lntervirology 38:63-74 (1995).
Zebedee, S.L., et al., “Characterization of the Influenza Virus M2 Integral Membrane Protein and Expression at the Infected-Cell Surface from Cloned cDNA,”J. Virology56:502-511 (1985).
Zebedee, S. L., et al., “Influenza A Virus M2 Protein: Monoclonal Antibody Restriction of Virus Growth and Detection of M2 in Virions,”J. Virology62(8): 2762-2772 (1988).
Katz, J.M. et al., “Immune Mechanisms of Protection Induced by Vaccination of BALB/c Mice with Influenza A Virus M2 Protein,” In:Options for the Control of Influenza III, Leo Brown, et al. (eds.), pp. 837-843 Elsevier, B.V., (1996).
Slepushkin, V.A., et al., “Protection of Mice Against Influenza a Virus Challenge by Vaccination with Baculovirus-Expressed M2 Protein,”Vaccine13:1399-1402 (1995).
Treanor, J.J. et al., “Passively Transferred Monoclonal Antibody to the M2 Protein Inhibits Influenza A Virus Replication in Mice,”Journal of D5 Virology, 64(3):1375-1377 (1990).
Black, R.A. et al., “Antibody Response to the M2 Protein of Influenza A Virus Expressed in Insect Cells”,Journal of General Virology74:143-146 (1993).
Hongo, S. et al., “Characterization of a Second Protein (CM2) Encoded by RNA Segment 6 of Influenza C Virus”,Journal of Virology71(4):2786-2792 (Apr. 1997).
Milich, D.R. et al., “The Hepatitis Nucleocapsid as a V
Fiers Walter
Jou Willy Min
Neirynck Sabine
Chen Stacy B
Husch Blackwell Sanders
Vlaams Interuniversitair Instituut Voor Biotechnologie
LandOfFree
Immunoprotective influenza antigen and its use in vaccination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoprotective influenza antigen and its use in vaccination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoprotective influenza antigen and its use in vaccination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237137